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Non-alcoholic fatty liver diseaseAnimal models have been widely used to investigate the relationship between diet and atherosclerosis
and also to study disease etiology and possible interventions. Guinea pigs have been suggested to be a
more “realistic” model for atherosclerosis due to their many similarities to humans. However, few published
studies actually reported observations of characteristic atherosclerotic lesions and even fewer of advanced
lesions. Studies, by our group, of guinea pigs fed on a high-fat diet revealed similar observations, with indi-
cations primarily of fatty streaks but little evidence of atherosclerotic plaques. This review discusses the fea-
sibility of the guinea pig as a model for dietary-induced atherosclerosis. As it stands, current evidence raises
doubt as to whether guinea pigs could serve as a realistic model for atherosclerosis. However, our own data
and the literature suggest that they could be useful models for studying lipoprotein metabolism,
non-alcoholic fatty liver disease, and dietary interventions which may help regulate these conditions.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity
and mortality in the US [1] and many developing countries [2]. Ath-
erosclerosis, the most common underlying cause of many CVDs, is
characterized by lipid and cholesterol deposition on the inner lining of
blood vessels, resulting in plaque formation and eventually narrowing
of the lumen [3]. The progression of atherosclerosis is known to involve
both an inﬂammatory response and oxidative damage, and consists of
numerous stages (of whichmost are clinically silent) leading to the de-
velopment of the atheroma, a pathological hallmark of atherosclerosis
(Fig. 1). Atherosclerosis usually commences with endothelial dysfunc-
tion and the subendothelial accumulation of lipid-laden macrophages,
termed foam cells. These form the fatty streaks which are present in
the coronary arteries during the ﬁrst decade of life and may even be
present in infants or fetal aortas [4–6]. In the intermediate lesion, the
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rights reserved.into the ﬁbrous cap encompassing the foam cells of the atheroma. The
foam cells later die forming a necrotic core, whereby rupture of the ﬁ-
brous cap will lead to thrombus formation. In the advanced lesion, the
further expansion of the ﬁbrous plaquemay lead to occlusion of the ar-
terial blood ﬂow, typically accompanied by calciﬁcation of the vessel
walls.
2. Animal models of atherosclerosis
The somewhat complex etiology of atherosclerosis has made clar-
iﬁcation of cellular and molecular interactions complicated. Animal
models however, provide an effective means for investigating these
mechanisms and associations. Many animal models have been used
to facilitate the study of disease etiology, investigate the relationship
between diet and atherosclerosis and uncover possible interventions.
The more common models include mice, rats, rabbits, hamsters and
guinea pigs generally fed an atherogenic diet, high in fat and/or cho-
lesterol to induce disease pathology. Nevertheless, no single animal
model is perfect. Mice or rats are not ideal for studying diet-induced
atherosclerotic changes because of their innate tolerance to high cho-
lesterol diets and considerably different plasma lipoprotein proﬁles to
humans (Fig. 2). Transgenic knockdown or knockout mouse models
have been used very successfully for investigating the disease mech-
anisms of atherosclerosis. Even then however, the disease progression
may differ mechanistically to the development of atherosclerosis in
humans and hence diet-induced disease parameters are still probably
best examined using unmodiﬁed animals [7].
The New Zealand white rabbit is perhaps one of the most widely
utilized and best studied genetically unmodiﬁed animals for athero-
sclerosis research as it readily develops hypercholesterolemia and
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ever, themajority of circulating cholesterol is present as high-density li-
poprotein (HDL), which again differs signiﬁcantly from humans where
low-density lipoprotein (LDL) predominates [8]. Furthermore, abnor-
mally high levels of dietary cholesterol are typically used to induce
symptoms usually within a very short period of time, leading to fatty
streaks which develop differently from those observed in humans, cast-
ing doubts as to the human relevance of ﬁndings in rabbits [9].
Hamsters, another commonly used animal for studying athero-
sclerosis, are believed to be a reasonable model due to their many
similarities with humans, including a low rate of endogenous cholester-
ol synthesis and similar lipoprotein metabolic enzymes. Unlike other
rodents, hamsters develop aortic lesions when fed on an atherogenic
diet [7]. However, hamsters also possess vastly different plasma lipo-
protein proﬁles from humans and development of lesions is reported
to be inconsistent and typically irreproducible [10].
3. The guinea pig as a model for atherosclerosis
3.1. The guinea pig model
Guinea pigs, on the other hand, have comparable lipoprotein proﬁles
to humans (Fig. 2), with LDL present as the major form of circulating
cholesterol and they have been used in several studies, althoughmostly
by certain groups, especially Fernandez et al. (multiple publications
utilizing guinea pigs to study effects of different dietary constituents,
antioxidants, gender differences and drug intervention on the devel-
opment of atherosclerosis; e.g. [9,10]). In addition, guinea pigs also
havemany other similarities to humans including comparable plasma li-
poprotein metabolism enzymes, a requirement for dietary vitamin C,
similar gender plasma lipoprotein differences and similar responses to
dietary interventions, exercise and drug treatment [9]. Despite these
similarities, guinea pigs have not usually been the ﬁrst choice of model
for investigating atherosclerosis and CVD and it is interesting to ask
why they are not more widely used.
3.2. What have we learned from guinea pig studies
3.2.1. Role of dietary cholesterol and fat on atherosclerotic lesion formation
While the association between atherosclerosis and diet was
established in the early 20th century [11], the exact relationship be-
tween this condition and individual dietary constituents is yet to be
fully elucidated [7]. Early on cholesterol was believed to be the primary
instigator of atherogenesis; hence cholesterol metabolism has been
studied in many different animal models. Cook et al. [12] investigated
cholesterol metabolism in rats, guinea pigs and rabbits and observed
very different responses between these animals when challenged
with high dietary cholesterol and fat. Rats andmice typically developed
fatty livers but suffered minimal cardiovascular complications, whereas
guinea pigs lost weight and developed enlarged fatty livers and spleens
(similarly observed by our group); rabbits maintained their weights
initially, but later as complications arose their appetite and weight de-
clined [12]. In rabbits there is an observable deposition of cholesterol
in the intima of the aorta, a build-up of lipid laden foam cells and
vascular smooth muscle cell remodeling, which are all characteristic
of lesion formation.
Numerous studies have suggested that initiation and development
of aortic lesions in guinea pigs can be inﬂuenced by diets containing
both high fat and high cholesterol. Guinea pigs fed higher concentra-
tions of cholesterol and fat (0.25% cholesterol and 26% fat) were
shown have greater cholesterol deposition in aorta compared with
control animals fed with 0.04% cholesterol and 15% fat [13]. Extended
duration of feeding with lower concentrations of cholesterol also led
to atherosclerotic pathology, with guinea pigs fed diets containing
0.15% cholesterol and high fat for 90 days followed by 0.2% cholester-
ol for a further 30 days reportedly developing aortic lesions [14]. Twoother similar studies feeding high cholesterol diets (0.5–1%) to guinea
pigs revealed cholesterol deposition and lesions present in the aorta
[15,16].
In 1968, Tararak [17] published a study demonstrating reversal
of atherosclerotic progression in the guinea pig model. These animals,
fed daily with cholesterol-rich egg yolks, developed atherosclerotic
plaques in the aorta after 9 months and were subsequently placed
back onto a normal diet. A decrease in plaque lipid content and in-
crease in collagen ﬁber formation was observed after 6 months and
by 12 to 18 months minimal lipid material was found in deep layers
of intima. However, complete removal of lipids was not observed
and re-absorption of lipids during the regression process was slow
and irregular, leaving behind cholesterol crystals and calciﬁcation
[17]. This demonstrated the ability to not only halt disease progres-
sion but also partially reverse the damage.
These aforementioned studies represent some of the few exam-
ples reporting lesion development in the guinea pig. Studies such as
that by Bernick et al. [18], feeding 1% cholesterol over 4 weeks, typically
only lead to early indications of atherosclerotic pathology (cholesterol/
lipid deposition, endothelial dysfunction and fatty streaks) in the aorta
and coronary arteries of these animals.
Contradictory to earlier studies, some groups found that feeding
lower levels of dietary cholesterol for longer periods also showed lit-
tle evidence of atherosclerotic development. Feeding guinea pigs with
a 0.5% cholesterol diet for 15 weeks showed a 25% increase in aortic
cholesterol content, but little indication of atherogenesis [16]. Anoth-
er group fed guinea pigs 0.25% cholesterol and 10.5% fat for 3 months
and observed no difference in aortic cholesterol content and no evi-
dence of atherosclerotic lesion formation in the aortic arch [19]. Sim-
ilar studies by our group have found that guinea pigs fed with 0.33%
cholesterol and 10% fat for 6 months, revealed signiﬁcantly elevated
plasma cholesterol level but little indication of atherosclerotic lesion
formation (Ye et al., unpublished).
Despite the lack of deﬁnitive lesions in the guinea pigs, evidence
shows that dietary cholesterol can inﬂuence plasma lipoprotein pro-
ﬁles, which are consequently known to elevate the risk of developing
atherosclerosis and cardiovascular-related pathologies in humans [3].
Puppione et al. [20] found that plasma HDL and LDL levels increased
when guinea pigs were fed with 1% cholesterol. Similarly, feeding a
lower level (0.25%) of dietary cholesterol resulted in a higher LDL
and very-low-density lipoprotein (VLDL) fractions but lower HDL [21].
3.2.2. Lesions in the guinea pig; do they model atherosclerosis in
humans?
While many studies have failed to generate atherosclerotic plaques
in the guinea pig, the few that report indications of lesions highlight
some distinct morphological differences between plaques present in
guinea pigs and humans. As with atherosclerosis in many other animal
models (including rats, mice and rabbits), guinea pigs do not develop a
diffuse intimal thickening, a characteristic observation prior to athero-
genesis in humans [22]. Amongst the few suspected plaques found in
cholesterol-fed guinea pigs in our study, pathology revealed a locally
thickened artery wall consisting of irregularly arranged foam cells, or
normally-looking non-foamy cells (Fig. 3a–d). Human atherosclerotic
plaques usually have a clear lipid core between tunica media and a ﬁ-
brous cap (Fig. 1b), which, however, was not observed in the suspected
guinea pig plaques (see examples in Fig. 3). Furthermore, no advanced
lesions have been observed and nor are they likely to be observed
due to the highly hepatotoxic effect of the high cholesterol diet (as will
be discussed later in Section 6) [23,24].
It is also important to note that although the plaques in guinea
pigs, like most other animal models, may develop over a matter of
weeks to months on a high cholesterol diet [25], an atherosclerotic
plaque in humans typically develops over years to decades. This high-
lights the fact that although short term therapies are viable and success-
ful in the animal models, they may not be translatable to humans. An
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eling and decreases macrophage foam cell inﬁltrations following ve-
nous graft, over 12 weeks of treatment but may not be applicable to
humans where macrophage inﬁltrations is usually observed after the
ﬁrst year of vein graft [26,27]. Furthermore, plaque regression and re-
versal of atherosclerosis have been clearly demonstrated in guinea
pigs and other animal models [28,29], however this is far less evidentFig. 2. Lipoprotein proﬁles of different animals in comparison to humans. Of the fre-
quently used animal models of atherosclerosis, the guinea pig has the closest lipopro-
tein proﬁle to that of humans.
Adapted from Fernandez et al. [9]).in humans often with plaque stabilization or slight reduction in plaque
volume being the best achievable outcome of therapy [30].3.2.3. Comparison between different studies and potential problems
Despite the frequent use of guinea pigs by certain groups as a re-
search model for atherosclerosis and metabolic disorders, the number
of accounts of aortic lesions in this animal model is limited, with many
studies only reporting fatty streaks or other preliminary indications of
early lesion formation [13–18,31–37]. A handful of studies induced
some lesion pathology using a variety of diets in the guinea pigs,
which are brieﬂy listed in Table 1 together with their differing methods
of measuring lesion progression, which also highlights the difﬁculty in
comparing these various studies.
A few other issues hamper comparisons between studies. Firstly,
few studies report the exact lipid compositions of their “high fat”
diets, which are essential in making comparisons, however these data
are rarely given. In addition, the composition of the pellet may also be
another important factor as carbohydrate content, ﬁber and other
constituents of the pellet may impact the progression of the disease
(as will be discussed later) or inﬂuence other metabolic pathways af-
fecting outcomes.
Secondly, the storage of the diet and the degree of oxidation of
lipids in the diet is rarely examined and may be a confounding factor
in many studies, since oxidized lipids themselves have pathological
effects (reviewed in [38,39]). Lipid peroxidation should be routinely
tested for in the diets, since oxidation of diets could lead to increased
artifactual oxidative damage in animals, and could inﬂuence disease
development. For example, a previous study showed that feeding oxi-
dized cholesterol resulted in a signiﬁcant increase in atherosclerotic le-
sion areas in apolipoprotein E (apoE) or LDL-receptor deﬁcient mice,
as well as a two-fold increase in lesion areas in rabbits, compared to
feeding non-oxidized cholesterol [40].
Thirdly, a wide range of cholesterol concentrations is used in the
diets, ranging from 0.15% to 1.7% cholesterol. Many earlier studies uti-
lized very high levels of cholesterol (1 to 1.7%) in their diets to elicit
pathological effects. However, the levels of cholesterol used in those
early studies may not be physiologically relevant to humans.
Lastly, differing feeding durations, environments and genetic
variability of animals are variables that make comparisons difﬁcult.Fig. 1. The typical disease progression of atherosclerosis. (a) The disease usually com-
mences with intimal inﬂux and accumulation of monocytes and low density lipoprotein
and dysfunction of the endothelium. Monocytes adhere and migrate across the endothe-
lium and become macrophages. The receptor- mediated uptake of oxidized-LDL by mac-
rophages leads to the formation of foam cells and in turn, fatty streaks. (b) As foam cells
accumulate further, the vascular smooth muscles migrate and proliferate, forming the ﬁ-
brous cap to seal in the developing necrotic core. (c) If the ﬁbrous cap thins out and rup-
tures, a massive inﬂammatory response and secretion of coagulation factors will lead to a
thrombus formation and associated complications, e.g. stroke, myocardial infarction. (d)
An advanced plaque may grow further and obstruct blood ﬂow.
(a) (b) 
(c) (d) 
Fig. 3. Examples of suspected atherosclerotic lesions from aortic sections from high cholesterol fed guinea pigs (hematoxylin–eosin staining); (a) and (b) from guinea pigs fed with
10% fat and 0.17% cholesterol diet; (c) (d) from guinea pigs fed with 10% fat and 0.33% cholesterol diet.
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leads to further progression of disease it remains unclear whether
guinea pigs can develop advanced atherosclerotic plaques or associ-
ated clinical symptoms through feeding of dietary cholesterol alone
for an extended period of time.
3.2.4. Gender differences
In humans atherosclerosis has been shown to be predominant
in males with higher prevalence observed in males relative to
premenopausal females across different age groups [41]. This resis-
tance appears to be abolished in women post menopause but has
been shown to be maintained with estrogen-replacement therapies
[42–44]. Similarly, this gender-speciﬁc susceptibility has been ob-
served in guinea pigs. Female guinea pigs were shown to have higher
HDL and lower LDL than males, whereas ovariectomized guinea pigs
were found to have higher plasma LDL, apolipoprotein B (apoB) and
triacylglycerol (TAG) thannormal female guinea pigs but stillmaintained
higher levels of HDL than males [45]. Furthermore, hepatic cholesterol
and TAG concentrations were highest in female guinea pigs, compared
to males or ovariectomized females [45].
Studies revealed that female guinea pigs were found to be less sus-
ceptible to the effects of dietary cholesterol and more responsive to
dietary soluble ﬁber when challenged with high cholesterol, com-
pared to males [46–49]. Similarly, female guinea pigs responded bet-
ter to the beneﬁcial effects of unsaturated dietary fat, compared to
males, however, this beneﬁt was negated following ovariectomy [45].
3.2.5. Age dependent susceptibility
The incidence of atherosclerosis signiﬁcantly increases with age,
however this is likely due to the subclinical nature of atherosclerosiswhich may develop for decades in humans [25,50]. However, this un-
likely to be the case in experimental guinea pig models because of the
typically extreme nature of the diets used to induce disease. While
there are no studies in guinea pigs investigating the increased suscep-
tibility with age, it is expected that various risk factors of atheroscle-
rosis will increase with age as has been shown in humans [51]. Indeed
it has been shown that older animals are higher in basal inﬂammatory
and oxidative stress levels compared to younger animals [52–54].
Most studies utilizing guinea pigs to investigate atherosclerosis had
initial body weights ranging from 250 to 1200 g (indicating less than
6 months of age) (e.g. [15,17–19,21,32–34,55–63], etc.). From the list
of studies only 4 gave indications of atherosclerotic lesions in the ani-
mals, however the age at which the studies commenced is quite vari-
able [17,18,32,34]. As previously mentioned, comparison is difﬁcult
to draw between those studies due to the large number of variables
(see Section 3.2.3). As it stands, no signiﬁcant age-related susceptibili-
ties to atherosclerosis have been observed in the guinea pig model
and further investigations are required to fully elucidate these effects.
4. Effects of dietary supplements in guinea pigs
Various supplements have been claimed to lower cholesterol
deposition and decrease lesion area, based on histological observa-
tions, in high fat and cholesterol fed guinea pigs. Furthermore, the ox-
idation of LDL is thought to play a major role in the progression of
atherosclerosis [64,65]. Some studies have shown that antioxidants
may inhibit foam cell formation and delay the progression of athero-
sclerosis [66–69].
These supplements includeα-tocopherol, Varespladib (a phospholi-
pase A2 inhibitor), lutein and grape powder extract [34–37].
Table 1
The following table indicates the few studies of the large number of guinea pig studies
that reported indications of atherosclerotic lesion formation. The table shows thewide va-
riety of diets used and differing methods of measuring lesion formation/development
making comparisons between studies difﬁcult.
Ref. Control Treatment Effect Measurements
[31] 10% fat 45% fat – % positive
staining area
[32] Chow 29% oleic acid added – Histological
description;
no speciﬁc
units
[14] 0.2% cholesterol in
normal diet
(30 days)+normal
diet (90 days)
0.2% cholesterol in normal
diet (30 days)+0.15%
cholesterol in high fat diet
(90 days)
↑ % lipid
laden-area/
intimal surface
[15] Rabbit chow Rabbit chow+1%
cholesterol
↑ Atherosclerotic
score
[13] Chow High cholesterol ↑ Cholesterol:
mmol/g wet
aorta
[13] Chow High cholesterol+high fat ↑ Cholesterol:
mmol/g wet
aorta
[16] Chow Chow+0.5% cholesterol ↑ Cholesterol:
μg/g fresh
aorta
[18] Control diet Control diet+1%
cholesterol
↑ Histological
description;
no speciﬁc
units
[17] Control diet Control diet+half yolk
daily
↑ Histological
description;
no speciﬁc
units
[33] Control diet
(0.33% cholesterol)
Control diet+10% soluble
ﬁber
↓ Fatty streak
area/total
intima area
(μm2/mm2)
[34] 15% fat+0.25%
cholesterol
15% fat+0.25%
cholesterol+drug A-002
↓ Histological
description;
no speciﬁc
units
[35] 2.5%
cholesterol+7.5% fat
2.5% cholesterol+7.5%
fat+Vitamin E
↓ Fatty streak
area/total
intima area (%)
[36] 0.33%
cholesterol+10%
sucrose
0.33% cholesterol+10%
grape powder
↓ Cholesterol:
mmol/g wet
aorta
[37] 0.25%
cholesterol+15% fat
0.25% cholesterol+15%
fat+0.1% lutein
↓ Histological
description;
no speciﬁc
units;
cholesterol:
mmol/g wet
aorta
359P. Ye et al. / Biochimica et Biophysica Acta 1832 (2013) 355–3644.1. Supplementation with antioxidants; ascorbic acid and α-tocopherol
Similarly to humans, guinea pigs are one of the few animals unable
to synthesize ascorbate [70]. Guinea pigs under subscorbutic conditions
(inadequate ascorbic acid), fed with dietary cholesterol (0.25 mg/100 g
body weight daily) for 2 months, were found to have accelerated indi-
cations of endothelial damage, perhaps an early stage of atherosclerosis
preceding lipid deposition, highlighting the ability of this nutrient to
delay pathogenesis [71].
Vitamin E is an overall term for several natural antioxidants. Vita-
min E was suggested to reduce the risk of atherosclerosis in some
animal studies [72–74]. However, results from human clinical trials
have not demonstrated a signiﬁcant effect on atherosclerosis progres-
sion, although oxidative markers were sometimes decreased [75–77].
Amongst these animal studies, one particular study revealed that
supplementing cholesterol-fed (2.5%) guinea pigs with vitamin E,was shown to decrease oxidative damage and increase integrity of the
vascular wall [35]. However, similarly to human studies, no signiﬁ-
cant effect on atherosclerosis progression was shown [35].
4.2. Supplementation with polyphenols
Polyphenols which exists in many natural foods have antioxidant
activities in vitro, however their actual activities as antioxidants in
vivo are uncertain (discussed in [38,78]). Polyphenols were shown
to have anti-atherosclerotic effects in several animal studies, however
these have not been clinically tested [79–83]. The effects of grape
polyphenols were studied in ovariectomized guinea pigs fed with high
(0.33%) cholesterol and they were found to lower plasma TAG and
VLDL levels, hepatic acyl-CoA: cholesterol acyltransferase (ACAT) activ-
ity and aortic cholesterol concentrations [36]. Extracts from the fruit of
the tree Garcinia atroviridis, rich in ﬂavonoids and hydroxycitric acid,
were shown to decrease TAG levels in plasma, as well as fat deposition
in aorta [15]. However, this could also be due to the effects of other
compounds in the extracts.
Inula racemosa (a ﬂowering plant from the Asteraceae family),
typically prescribed in TCM for precordial chest pain, was studied in
guinea pigs previously maintained on a high cholesterol (0.2%) diet
for 30 days. Supplementation with the I. racemosa extract (100 mg/kg)
for 90 days, was able to reduce atherosclerotic lesion size relative to
untreated animals in addition to decreasing plasma cholesterol, TAG,
LDL levels, atherogenic index (LDL/HDL), and increased HDL levels. A
decrease in lipid peroxidation levels (measured by TBARS; a somewhat
questionable and unreliable biomarker [38]) and an increase in reduced
glutathione levels were also observed in the liver together with an in-
crease in the antioxidant enzymes, superoxide dismutase and glutathi-
one peroxidase, in the heart [14].
4.3. Supplementation with lutein
The carotenoid lutein, synthesized in high concentrations by cer-
tain ﬂowers and green leafy vegetables was found to have protective
effects against early atherosclerotic events [84]. Supplementing high
cholesterol-fed guinea pigs with 0.1% lutein for 12 weeks, was shown
to decrease both plasma and aortic LDL, oxidized LDL (ox-LDL) and
lipid peroxidation levels (as determined by the questionable biomarker
[38], TBARS), as well as lowering levels of cytokines [37]. The lutein
concentrations supplemented to the animals were found to negatively
correlate to ox-LDL levels in both plasma and aorta, indicating that lu-
tein might potentially exert antioxidant and anti-inﬂammatory effects
in aortic tissues [37].
4.4. Supplementation with soluble ﬁber
Supplementing high cholesterol fed guinea pigs with 10% soluble
ﬁber was also claimed to impair aortic lesion development [33]. Sim-
ilarly, with intake of soluble ﬁber, both male and female guinea pigs
showed lower susceptibility to LDL oxidation, while no effects were
observed in ovariectomized guinea pigs [85]. Conversely, other die-
tary changes such as alteration of the carbohydrate to fat ratio or sup-
plementation with an oleic acid enriched diet, which were previously
believed to counteract cholesterol deposition, did not affect lipid build-
up or lesion areas in guinea pigs [31,32].
5. Drug interventions
5.1. Effect of statins and cholesterol regulating compounds in cholesterol-fed
guinea pigs
Statins are widely used to lower blood cholesterol through inhibi-
tion of HMG-CoA reductase, a rate-limiting enzyme in cholesterol
synthesis [86]. Clinical trials have demonstrated the efﬁciency of
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lying mechanisms have been investigated in various animal models,
including guinea pigs [86,88–90].
The effects of one particular statin, atorvastatin, were studied in
guinea pigs fed with high fat (15%) and cholesterol (0.04%) revealing
a dose-dependent decrease in plasma LDL levelswith increasing atorva-
statin (1–20 mg/kg). This was accompanied by decreased apoB and
cholesteryl ester and increased TAG in VLDL and LDL particles. Further-
more, hepatic ACAT activity decreased and apoB/E receptor expressions
were elevated with increasing doses of atorvastatin, indicating that the
effects of the statin are connected to hepatic cholesterol metabolism
[91].
A similar study compared the effects of atorvastatin with another
statin, simvastatin, revealing similar LDL cholesterol lowering abilities
of the two compound with only slight differences in their effect on
cholesterol metabolism [92]. Both statins reduced plasma apoB, he-
patic free cholesterol levels, and susceptibility of LDL particles to ox-
idation, however, only atorvastatin decreased ACAT activity [92].
The above observations of atorvastatin and simvastatin in guinea
pigs generally correlate with those in humans. Both statins demonstrat-
ed the ability to lower plasma total and LDL cholesterol in humans [93],
similarly to what was observed in guinea pigs [91,92]. Atorvastatin was
shown to be weaker in raising plasmaHDL than simvastatin, in humans
[94]. However, in contrast to the observations in humans, both statins
were found to decrease plasma HDL in guinea pigs [92]. Sitostanol,
another cholesterol lowering compound has also similarly demonstrat-
ed plasma LDL, hepatic cholesterol and TAG lowering capabilities in
guinea pigswhile increasing cholesterol excretion [95]. Despite their ef-
fectiveness, myopathy remains a potentially problematic side effect of
this treatment [96]. In addition to testing the efﬁcacy of statins, guinea
pigs provide a useful model to investigate themyotoxicity of these cho-
lesterol lowering compounds before preclinical studies [97].
5.2. Effect of microsomal triglyceride transfer protein and phospholipase
A2 inhibitors
Microsomal triglyceride transfer proteins (MTP) are known to
play a role in lipoprotein assembly and inhibitors of them have dem-
onstrated the ability to lower plasma lipid (mainly TAG) levels [98].
One such MTP inhibitor, JTT-130 (0.0015%), was shown to reduce plas-
ma LDL and TAG levels and cholesteryl ester transfer protein activity in
cholesterol (0.08%) fed guinea pigs alongside atorvastatin [98].
Increased serum levels of secretory phospholipase A2 were found
to be associated with certain cardiovascular disorders [99]. The daily
administration of Varespladib, a phospholipase A2 inhibitor, to high
fat (15%) and cholesterol (0.25%) fed guinea pigs, lowered cholesterol
accumulation in the aorta and reduced levels of inﬂammatory cyto-
kines including IL-10 and IL-12 [34]. Those observations in guinea
pigs are somewhat similar to clinical observations in humans demon-
strating decreases in LDL and VLDL cholesterol, reduced levels of
ox-LDL and high-sensitivity C-reactive protein in patients adminis-
tered Varespladib [100].
6. Fatty liver disease
6.1. Effect of high cholesterol on the liver
Dietary cholesterol is known to pass the liver before it can enter the
plasma. When presented with excess dietary cholesterol, the liver may
compensate by decreasing the endogenous cholesterol synthesis and
increase cholesterol excretion to help maintain plasma cholesterol ho-
meostasis [101]. Lin et al. [102] found that guinea pigs could maintain
normal plasma cholesterol levels until supplemented dietary cholester-
ol was equal or greater than the amount synthesized endogenously.
After just 1 week of feeding guinea pigs 1% dietary cholesterol, an accu-
mulation of lipids in the liver was observed by histology supporting theview that damage from high dietary cholesterol commences in liver
[103]. Increases in hepatic cholesteryl esters and lysosomal enzyme
activities were observed which also indicate excess lipid deposition
in hepatocytes [104]. Similarly, our own studies (unpublished)
have found that guinea pigs fed with 0.33% cholesterol and 10% fat
for 8–24 weeks developed enlarged livers with elevated markers of
liver damage (including alanine transaminase and gamma glutamyl
transpeptidase activities) and histological evidence of fatty deposits.
However, we observed little or no indication of aortic atherosclerotic
lesions, certainly no greater than age-matched control animals, at up
to 6 months of feeding.
6.2. Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is themost common cause
of chronic liver disease in Western countries nowadays, whose pathol-
ogy resembles alcohol-induced liver injury [105,106]. NAFLD comprises
a range of related hepatic disorders including simple steatosis, non-
alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcino-
ma (HCC) [107]. It is widely accepted that NAFLD is closely related to
an excess intake of calories, obesity, and insulin resistance, and it is
therefore considered as a hepatic manifestation of metabolic syndrome
[108,109]. Obesity and insulin resistance can lead to an increase in free
fatty acid (FFA) uptake by hepatocytes and also an increase in hepatic
FFA synthesis, which causes imbalance between uptake/synthesis and
oxidation/export of fatty acid and accumulation of triglycerides in hepa-
tocytes [106]. FFA overload in hepatocytes can lead to greater produc-
tion of reactive oxygen species both by over-reduced mitochondrial
electron transport chains (O2•− and H2O2) and increased FFA oxidation
by peroxisomes and microsomes (H2O2) [110]. Injury of hepatocytes
by oxidative stress can subsequently lead to death by necrosis or apo-
ptosis. Lipid peroxidation products and cytokines are released from
dead hepatocytes, and some can trigger the activation of Kupffer cells
and hepatic stellate cells, leading to inﬂammation and ﬁbrosis of the
liver [111,112].
One the other hand, NAFLD is also found in non-obese patients,
which can be associated with elevated dietary cholesterol (also lower
dietary polyunsaturated fatty acids), compared to obese patients
[113]. Clinical studies have shown that a cholesterol absorption inhibi-
tor can decrease hepatic injury in non-obese patients, which conﬁrms
a role of cholesterol in NAFLD development [114]. Liver X receptor
α (LXRα) was found to mediate this pathway, which can be activated
by cholesterol oxidation products (oxysterols) [115,116]. LXRα can ac-
tivate sterol regulatory element-binding protein 1c (SREBP-1c) and
carbohydrate response element binding protein (ChREBP) which in
turn activate several downstream factors, while activation of those fac-
tors would increase the synthesis of fatty acids in liver which may lead
to hepatic steatosis and later hypertriglyceridemia [117,118].
6.3. Animal models of NAFLD
Several types of genetically modiﬁed mice models have been gen-
erated and used to study the pathogenesis of NAFLD, which include
acyl-coenzymeA oxidase null (ACOX−/−)mice [119], nuclear respirato-
ry factor 1 null (NRF1−/−) mice [120], methionine adenosyltransferase
1A null (MTA1A−/−) mice [121], phosphatase tensin homolog null
(PTEN−/−) mice [122], and leptin deﬁcient mice [123,124]. Those gene
modiﬁcations can cause disturbance in hepatic lipid metabolism and
animals can develop NASH and also spontaneously HCC [125]. While
these genetically modiﬁed mice are useful in studying the mechanism
of NASH, especially the progression from NASH to HCC, they are not
suitable models for studying diet-induced NAFLD, since the pathogene-
sis of NAFLD in these mice does not resemble that of NAFLD in humans
(absence of ﬁbrosis and non-distinctive phases of steatosis) [125].
The methionine- and choline-deﬁcient (MCD) diet is a classical
dietary model for NAFLD, which contains high sucrose and fat but
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oxidation and formation of VLDL [126]. Mice fed a MCD diet develop
severe hepatic steatosis, inﬂammation, and elevated oxidative stress.
However, this model is a nutritional deﬁciency model which again
differs from typical NAFLD in human patients, who are usually
obese and overnutritioned. Therefore, studies using the MCD model
should be treated with caution.
Another dietary model for NAFLD, high fat diet (HFD) model, was
found to induce hepatic steatosis and NASH in animals, with raised
oxidative stress and ﬁbrosis [127]. Unlike other models, HFD-fed rats
develop obesity and insulin resistance, which is similar to human
NAFLD [128]. Those ﬁndings suggest that HFD-fed rats are a good
model for studying dietary-induced NAFLD.
Although very few studies used guinea pig as the animal model for
NAFLD, some of them have shown pathological evidence of hepatic
steatosis after feeding the animals with high cholesterol diets. These
include a 1% cholesterol diet for 8 weeks [129] and 0.25% cholesterol
diet for 12 weeks [130]. Our own studies also found similar patholog-
ical evidence of NAFLD (enlarged fatty liver and spleen).
Previous studies have shown a close relationship between NAFLD
and atherosclerosis [131–133]. Similar to atherosclerosis, several risk
factors of NAFLD are common for both guinea pigs and humans, such
as atherogenic hyperlipidemia (similar lipid metabolism and plasma
lipid proﬁle), and systemic inﬂammation (similar immunologic re-
sponse), male gender (female gender protected), lack of exercise
(similar response to exercise) and high fat diet (similar response to di-
etary fat) [9,134]. All those similarities with humansmake guinea pigs a
potentially good animal model for studying NAFLD, especially its rela-
tionship with atherosclerosis.7. Conclusion
Despite a greater understanding of the condition, atherosclerosis
remains the greatest cause of morbidity and mortality in many devel-
oped nations [135]. This highlights the need to critically evaluate
whether current disease models are feasible for expanding our cur-
rent depth of knowledge on atherosclerosis. Animal models are widely
used to investigate disease mechanisms and interventions for athero-
sclerosis. However, many models utilize unrealistically high levels of
cholesterol and fat to induce cardiovascular or atherosclerotic pathology
over very short periods of time, and hence the molecular mechanisms
seen in these models may not be translatable to humans. Consequently,
there is a need for more convincing animal models through which
the ﬁndings can be relatable to humans. There is possibly also, a need
to standardize diets as rarely is the exact composition and oxidation
state of the “high fat” speciﬁed.
Guinea pigs were found to have many similarities with humans
and were suggested as a more “realistic” model for atherosclerosis
[9]. Indeed numerous studies in guinea pigs have revealed a wide
array of similarities to humans. In addition, guinea pigs seem to have
similar responses to dietary challenges with high fat and cholesterol,
degree of fatty acid saturation, carbohydrate restriction, soluble ﬁber,
antioxidants, or pharmaceutical interventions.
While the guinea pig model makes sense because of its many sim-
ilarities in lipoprotein proﬁle and cholesterol metabolism to humans,
the difﬁculties in developing atherosclerotic pathology may not make
this the best model for studying this condition. Despite a large num-
ber of guinea pig studies, very few report observations of atheroscle-
rotic lesions and there have been no reports of advanced lesions being
seen in the guinea pig. Two earlier studies which revealed plaques
utilized longer treatment duration and higher dietary cholesterol to in-
duce plaque formation. It may be possible however that other compo-
nents of the egg yolks (fed to the guinea pigs), high casein or sucrose,
or oxidation of fats in the diets, could have contributed or played a
major role in the development of lesions in these early studies [17,18].Overall analysis of the studies however reveals that amongst other
dietary factors, total fat content and type of fat, play a crucial role in
atherogenesis. Studies demonstrated that different sources of dietary
fat (including olive oil, rapeseed oil, corn oil, corn husk oil, oleic
acid-enriched oil, and ω-3-enriched oil) revealed signiﬁcant differ-
ences in their effect on the animal plasma lipoprotein proﬁles, likely
due to variations in fatty acid composition [19,32,57,136–138]. Since
different studies obtain their guinea pig diets from wide range of
vendors that in turn use fats from a variety of different sources (with
different fatty acid compositions) to achieve the desired percentage
in the diet, this may highlight one of the reasons for highly variable
outcomes of different studies. Another possible factor to consider is
the oxidation of fats in the diets due to improper storage or during
transportation, which could signiﬁcantly inﬂuence the development of
lesions. However, very few studies check for this or gave any indication
it was controlled through proper storage (refer Section 3.2.3).
A possible reason why so few studies report the presence of ath-
erosclerotic lesions may be due to the restricted treatment periods
used; with the longest dietary intervention in guinea pigs spanning
9 months, which only displayed endothelial damage, lipid deposition
and early atheroma formation [17]. Even with increased cholesterol
levels (at up to 1% cholesterol), only lipid deposition was observed
[18], while studies with lower dietary cholesterol content demon-
strated even less evidence for lesion development. Studies by our
group revealed similar observations, with indications of fatty streaks
but no evidence of any advanced atherosclerotic lesions in guinea pigs
fedwith 0.33% cholesterol and 10% fat for 6 months (unpublished data).
On the other hand, our own research, together with current liter-
ature indicates that the guinea pig may be a suitable model for inves-
tigation of NAFLD. While it may appear that the time was insufﬁcient
to generate atherosclerotic lesions in the guinea pigs, investigations
revealed the development of grossly enlarged fatty livers. Liver dam-
age as indicated by appearance, histology and liver function tests was
observed from as early as 2 months with only a moderate 0.17% cho-
lesterol and 10% fat diet. Due to this, it is likely that the animals may
die from liver complications before the development of any athero-
sclerotic lesions, and indeed we observed many animals on the high
cholesterol and fat diet for 6 months beginning to lose weight and
show signs of deterioration. It would seem that guinea pigs, like
other rodents, are quite resistant to dietary-induced atherosclerosis,
which raises doubts as to the feasibility of guinea pigs as a suitable
model for atherosclerosis.
Furthermore it is unknown whether these lesions would be simi-
lar to those found in humans and further studies with much longer
feeding durations would be needed to answer this and other ques-
tions. As it stands however, current evidence, raises doubt as to
whether guinea pigs could serve as a realistic model for atheroscle-
rosis, however they may be useful models for studying lipoprotein
metabolism and NAFLD and dietary interventions to regulate these
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